Evidence map›Paper›PMID 33298762›Full record

Trial reportThe Pediatric infectious disease journal2021

Impact of Streptococcus salivarius K12 on Nasopharyngeal and Saliva Microbiome: A Randomized Controlled Trial.

Suvi Sarlin, Mysore V Tejesvi, Jenni Turunen, Petri Vänni, Tytti Pokka, Marjo Renko, Terhi Tapiainen

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Pediatric infectious disease journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05840926 (Possible Prophylactic Role of the S. Salivarius K12 Probiotic Strain for the Upper Respiratory Tract Infection and Nursery-age Children), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05840926 nacompletednot on this mapstarted 2022, after this paper: background citation

Possible Prophylactic Role of the S. Salivarius K12 Probiotic Strain for the Upper Respiratory Tract Infection and Nursery-age Children

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2022 to 2023Enrolled287ConditionsUpper Respiratory Tract InfectionArmsProbiotic Streptococcus salivarius K12, No probiotic supplementation
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Suvi SarlinFrom the Department of Pediatrics and Adolescent Medicine, Oulu University Hospital.
Mysore V TejesviGenetics and Physiology, Faculty of Science, University of Oulu.
Jenni TurunenGenetics and Physiology, Faculty of Science, University of Oulu.
Petri VänniGenetics and Physiology, Faculty of Science, University of Oulu.
Tytti PokkaFrom the Department of Pediatrics and Adolescent Medicine, Oulu University Hospital.
Marjo RenkoPEDEGO Research Unit and Medical Research Center Oulu.
Terhi TapiainenFrom the Department of Pediatrics and Adolescent Medicine, Oulu University Hospital.
University of Oulu · FIOulu University Hospital · FIKuopio University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProbiotic lactobacilli have been ineffective in preventing acute otitis media. In contrast to lactobacilli, alpha-hemolytic streptococci belong to the core microbiome of nasopharynx.

methodsWe investigated the effects of Streptococcus salivarius K12 probiotic on the saliva and nasopharyngeal microbiome in 121 children attending daycare. Children were randomly allocated to receive oral K12 product for 1 month or no treatment. We obtained saliva and nasopharyngeal samples at study entry, at 1 and 2 months. The next-generation sequencing of the bacterial 16S gene was performed.

resultsAfter the intervention, the diversity of saliva or nasopharyngeal microbiome did not differ between groups. The proportion of children with any otopathogen did not differ between the groups. At 1 month, the abundance of otopathogens in nasopharynx was lower in K12 group compared with that in control children (34% vs. 55%, P = 0.037). When we compared each otopathogen separately, Moraxella was the only group lower in the treatment group. We could not verify the reduction of Moraxella when an alternative Human Oral Microbiome Database taxonomy database was used. In children receiving K12 product, the mean abundance of S. salivarius was greater in saliva after the intervention (0.9% vs. 2.0%, P = 0.009).

conclusionsThe use of S. salivarius K12 probiotic appeared to be safe because it did not disrupt the normal microbiome in young children. Even though a short-term colonization of S. salivarius was observed in the saliva, the impact of S. salivarius K12 probiotic on the otopathogens in nasopharyngeal microbiome remained uncertain.

Indexed as

Streptococcus salivariusAdministration, OralChild, PreschoolFemaleHigh-Throughput Nucleotide SequencingHumansMaleMicrobiotaNasopharynxProbioticsRNA, Ribosomal, 16SSalivaSequence Analysis, RNARNA, Ribosomal, 16S

Identifiers

PMID33298762
PMCPMC8043514
OpenAlexW3112703608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.